Reference
- Albert J, Hosey T, LaMoreaux B, et al. Subcutaneous or oral methotrexate exposure and response to pegloticase in uncontrolled gout patients in a community rheumatology practice [abstract 1236]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).
Michele B. Kaufman, PharmD, BCGP | Issue: February 2020, January 2020 |
Reference
A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…
Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric acid (PUA) to less than 6…
In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:
The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.